Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis

Huang, Kaijun; Pan, Yihui; Shu, Guannan; Yao, Haohua; Liu, Xi; Zhou, Mi; Wei, Jinhuan; Chen, Zhenhua; Lü, Jun; Chen, Wei; Han, Hui; Zheng, Zhaohui; Luo, Junhang; Zhang, Jiaxing

doi:10.1016/j.canlet.2021.10.003

Cited by 24 publications

(17 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among 26 studies with a total of 2048 patients, the expression of six circRNAs (circ‐0001451, circ‐RAPGEF5, circ‐AMOTL1L, circ‐ESRP1, circ‐CYP24A1, and circ‐DVL1) was downregulated, 34,43,57,58,62,63 whereas 18 circRNAs (circ‐001895, circ‐001287, circ‐HIPK3, circ‐PDK1, circ‐MYLK, circ‐0085576, circ‐PTCH1, circ‐400,068, circ‐NUP98, circ‐001842, circ‐RS‐7 (two studies), circ‐AKT1, circ‐SDHC (two studies), circ‐TLK1, circ‐SNX6, circ‐0054537, circ‐CHST15, and circ‐PPP6R3) were upregulated in the RCC tissue 37–39,42,44,46–56,59–61,64 (Table S1). The tumor suppressor (downregulated) circRNAs were associated with smaller tumor size (OR = 0.71 [95% CI 0.58–0.87]; p = 0.001), lower T stage (OR = 0.45 [95% CI 0.27–0.75]; p = 0.002), less lymph node metastasis (OR = 0.29 [95% CI 0.12–0.72]; p = 0.008), less distant metastasis (OR = 0.24 [95% CI 0.14–0.41]; p < 0.001), and lower TNM stage (OR = 0.36 [95% CI 0.24–0.56]; p < 0.001).…”

Section: Resultsmentioning

confidence: 99%

“…In this regard, separate analyses were performed to pool HRs obtained from univariate and multivariate analyses. In multivariate analysis, the results were adjusted for age, [34][35][36][37][38][39] gender, [34][35][36]38,39 tumor grade, 34,[36][37][38][39][40][41][42] tumor/clinical stage, [34][35][36][37][39][40][41][42][43][44] tumor size, 36,40,43,44 metastasis, 34,35,[41][42][43] and surgical margin. 40 Sensitivity analysis was also performed to evaluate each study's impact on the pooled HRs by omitting one study at a time from the meta-analysis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circular RNAs as prognostic and diagnostic biomarkers in renal cell carcinoma

Rashedi

Mardani

Rafati

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Circular RNAs (circRNAs) play pivotal roles in proliferation, apoptosis, migration, and invasion of renal cell carcinoma (RCC) cells. This study is aimed to systematically summarize the current evidence regarding the clinical implications of circRNAs in RCC patients. Methods A systematic search in PubMed, Embase, and Web of Science was performed until January 1, 2022. The correlation between the expression of circRNAs and clinicopathological, prognostic, and diagnostic features of RCC was evaluated using the meta‐analysis. Results Ultimately, 41 studies with 3485 RCC patients were included in this study: 26 studies for clinicopathological features, 31 studies for prognosis, and eight studies for diagnosis. Altered expression of circRNAs was significantly associated with clinicopathological characteristics of RCC, including tumor size, tumor stage, lymph node metastasis, distant metastasis, and TNM stage. The tumor promoter circRNAs were associated with reduced overall survival (OS) (Hazard Ratio (HR) = 1.98, 95% confidence interval [CI] 1.68–2.34) and disease/progression/recurrence‐free survival (DFS/PFS/RFS) (HR = 2.34, 95% CI 1.85–2.97). Contrarily, the tumor suppressor circRNAs were linked with better OS (HR = 0.49, 95% CI 0.40–0.60) and DFS/PFS/RFS (HR = 0.40, 95% CI 0.28–0.59). The pooled sensitivity and specificity of circRNAs for RCC diagnosis in tissue samples were both 0.84. These results in fluid samples (serum and urine) were 0.78 and 0.69, respectively. Conclusion CircRNAs can serve as promising diagnostic and prognostic biomarkers for RCC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Circular RNAs as prognostic and diagnostic biomarkers in renal cell carcinoma

Rashedi

Mardani

Rafati

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Huang et al found that the expression of cicrSNX6 (hsa_circ_0031607) was up-regulated in sunitinib-resistant renal cancer cell lines by RNA-seq, and verified that circSNX6 can sponge miR-1184 and inhibit Glycerophosphocholine Phosphodiesterase 1 (GPCPD1), and then increased the content of Lysophosphatidic Acid (LPA) in cells, which eventually led to the enhancement of drug resistance of renal cancer cells to sunitinib [ 51 ]. The expression of circSNX6 was also significantly upregulated in hepatocellular carcinoma and its function in hepatocellular carcinoma has not been determined [ 52 ].…”

Section: Circrnas and Drug Resistance In Rccmentioning

confidence: 99%

Circular RNAs and Drug Resistance in Genitourinary Cancers: A Literature Review

Long

Shi

et al. 2022

Cancers

View full text Add to dashboard Cite

In recent years, systematic treatment has made great progress in genitourinary tumors. However, some patients develop resistance to the treatments, resulting in an increase in mortality. Circular RNAs (circRNAs) form a class of non-coding RNAs with high stability and significant clinical relevance. Accumulating evidence indicates that circRNAs play a vital role in cancer development and tumor chemotherapy resistance. This review summarizes the molecular and cellular mechanisms of drug resistance mediated by circRNAs to common drugs used in the treatment of genitourinary tumors. Several circRNAs were identified to regulate the responsiveness to systemic treatments in genitourinary tumors, including chemotherapies such as cisplatin and targeted therapies such as enzalutamide. Canonically, cicrRNAs participate in the competing endogenous RNA (ceRNA) network, or in some cases directly interact with proteins, regulate downstream pathways, and even some circRNAs have the potential to produce proteins or polypeptides. Several cellular mechanisms were involved in circRNA-dependent drug resistance, including autophagy, cancer stem cells, epithelial-mesenchymal transition, and exosomes. The potential clinical prospect of circRNAs in regulating tumor drug resistance was also discussed.

show abstract

“…Circ-CD44 promotes KRAS expression through adsorption of miR-502-5p, thereby promoting TNBC proliferation, migration, and invasion. Circ-SNX6 acts as a molecular “sponge” to attenuate the inhibitory effect of miR-1184 on its target gene GPCPD1, thereby increasing intracellular lysophosphatidic acid levels, ultimately promoting resistance to sunitinib in renal cell carcinoma cells ( Huang et al, 2021 ).…”

Section: Acts As a Competitive Endogenous Rnamentioning

confidence: 99%

Emerging Role and Mechanism of circRNAs in Pediatric Malignant Solid Tumors

Shen

Liu

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Circular RNAs (circRNAs) are non-coding RNAs with covalent closed-loop structures and are widely distributed in eukaryotes, conserved and stable as well as tissue-specific. Malignant solid tumors pose a serious health risk to children and are one of the leading causes of pediatric mortality. Studies have shown that circRNAs play an important regulatory role in the development of childhood malignant solid tumors, hence are potential biomarkers and therapeutic targets for tumors. This paper reviews the biological characteristics and functions of circRNAs as well as the research progress related to childhood malignant solid tumors.

show abstract

Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis

Cited by 24 publications

References 36 publications

Circular RNAs as prognostic and diagnostic biomarkers in renal cell carcinoma

Circular RNAs as prognostic and diagnostic biomarkers in renal cell carcinoma

Circular RNAs and Drug Resistance in Genitourinary Cancers: A Literature Review

Emerging Role and Mechanism of circRNAs in Pediatric Malignant Solid Tumors

Contact Info

Product

Resources

About